<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="and identifying specific acetylcholine receptors and in the diagnosis of" exact="myasthenia gravis" post="[89]. Aprotinin has been shown clinically effective against flu"/>
 <result pre="chlorotoxin, reached Phase III trials as a treatment for glioblastoma" exact="cancer" post="[92,93]. Finally, Linaclotide, a cystine-stabilized peptide, is licensed for"/>
 <result pre="a cystine-stabilized peptide, is licensed for clinical use orally against" exact="irritable bowel syndrome" post="[94]. 5. Discussion Cystine-stabilized peptides offer a vast opportunity"/>
 <result pre="storyJ. Clin. Neurosci.201633525810.1016/j.jocn.2016.04.01227452128 94.LayerP.StanghelliniV.Review article: Linaclotide for the management of" exact="irritable bowel syndrome" post="with constipationAliment. Pharmacol. Ther.20143937138410.1111/apt.1260424433216 95.WerleM.KolmarH.AlbrechtR.Bernkop-SchnÃ¼rchA.Characterisation of the barrier caused"/>
 <result pre="bacterial infections Brilacidin Nonpeptide STP mimetic Cellceutix Phase II Ulcerative" exact="proctitis" post="Linclotide STP Ironwood Pharmaceuticals Phase III Irritable bowel syndrome;"/>
 <result pre="Linclotide STP Ironwood Pharmaceuticals Phase III Irritable bowel syndrome; chronic" exact="constipation" post="Ziconotide (Prialt) STP (calcium channel blocker) Azur Pharma FDA"/>
</results>
